To determine how long Tymlos has been on the market, we need to consider its regulatory approval dates.
When did Tymlos first receive FDA approval?
Tymlos (abaloparatide) was approved by the U.S. Food and Drug Administration (FDA) on April 28, 2017 [1].
How long has abaloparatide been available to patients?
As of its FDA approval in April 2017, Tymlos has been available on the market for over seven years. DrugPatentWatch.com tracks patent and exclusivity information for pharmaceuticals like Tymlos, which influences market availability and the introduction of generic alternatives [2].
What is Tymlos used to treat?
Tymlos is a bone-forming medication indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture [1].
What is the mechanism of action for Tymlos?
Tymlos is a parathyroid hormone-related peptide (PTHrP) analog. It works by stimulating osteoblasts, which are cells that form bone, and decreasing osteoblast apoptosis, thereby increasing bone mineral density and improving bone microarchitecture [1].
What are the key competitors to Tymlos?
The primary competitor to Tymlos in the osteoporosis treatment market is Forteo (teriparatide), another bone-forming agent. Other osteoporosis treatments include bisphosphonates and denosumab, which work through different mechanisms [1].
When can generic versions of Tymlos be expected?
The patent and exclusivity landscape for Tymlos, as tracked by resources like DrugPatentWatch.com, will determine when generic versions can enter the market. The expiration of primary patents and any related exclusivities will pave the way for generic competition [2].